Skip to content

Predicting Endometrial Receptivity for Optimal Reproductive Management

Predicting Endometrial Receptivity for Optimal Reproductive Management (PERFORM)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04107129
Acronym
PERFORM
Enrollment
76
Registered
2019-09-27
Start date
2020-07-01
Completion date
2024-07-30
Last updated
2024-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis, Infertility, Female

Keywords

Infertility, Endometriosis, BLC6, SIRT1, In Vitro Fertilization (IVF), Embryo Transfer (ET), Frozen Embryo Transfer (FET), Assisted Reproductive Technology (ART), PERFORM

Brief summary

The purpose of this study is to understand why some women are infertile (unable to conceive a child). The investigators hope to learn if an endometrial biopsy after egg retrieval is feasible for detecting biomarkers for endometriosis and predicting implantation and pregnancy rate after embryo transfer. This study design will provide for the first time, an opportunity to compare endometrial biopsy material from hyperstimulated (gonadotropin treated) subjects after egg retrieval. If successful, it would provide a new protocol for women with unexplained infertility or those with known endometriosis to avoid poor IVF outcomes.

Detailed description

The investigators will recruit 100 women who are undergoing IVF with egg retrieval and delayed embryo transfer to consent to endometrial biopsy 1 week after egg retrieval. Currently most women in the Stanford's IVF program undergo egg retrieval with delayed embryo transfer (ET) with preimplantation genetic testing of embryos. This delay allows most to avoid the condition known as ovarian hyperstimulation and allows time for genetic screening (PGT-A) performed on embryos. Such a delay also opens the window for endometrial assessment for proteins like SIRT1 and BCL6 that have been suggested to be associated with endometriosis. Endometriosis is thought to cause IVF failure (Littman et al., 2002); by treating endometriosis in the future, clinicians might avoid IVF failure due to an unexpected non-receptive endometrium (Littman et al., 2002). This study design will provide for the first time, an opportunity to compare endometrial biopsy material from hyperstimulated (gonadotropin treated) subjects after egg retrieval. If successful, it would provide a new protocol for women with unexplained infertility or those with known endometriosis to avoid poor IVF outcomes. There is some evidence that endometrial scratching (biopsy) may enhance embryo attachment in future cycles (Vitagliano et al., 2018), although not all studies agree (Lensen et al., 2019). The endometrial biopsy taken in the secretory phase will be tested for BCL6 and SIRT1 expression, two proteins highly associated with the presence of endometriosis (Yoo et al., 2017). The samples of endometrium will be processed (put into formalin and paraffin blocks or saved in RNA later and not be analyzed until after completion of the ART cycle. Patients as well as the clinicians will be blinded to results and until the conclusion of the ART cycle following embryo transfer and subsequent pregnancy testing. This will be done to avoid interfering with the current ART cycle and to avoid the introduction of bias. Patients will be provided with test results after completion of the first embryo transfer if they wish to know.

Interventions

PROCEDUREEndometrial Biopsy

An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial tissue will be tested for BCL6 and SIRT1 Biomarkers

OTHEREuploid embryo transfer

Patients undergoing IVF and Preimplantation genetic testing will undergo delayed euploid frozen embryo transfer per clinical protocol and standard of care.

DIAGNOSTIC_TESTBlood sample

Estradiol and Progesterone levels in the blood will be checked

Sponsors

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
Stanford University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 42 Years
Healthy volunteers
No

Inclusion criteria

1. Age - 18 to 42 2. AMH ≥ 1 3. Planning to undergo IVF with delayed embryo transfer 4. Must have blastocyst(s) by day 6 that were biopsied for PGT-A 5. BMI 18-35

Exclusion criteria

1. Uterine fibroids \> 4 cm in size 2. Polycystic ovary syndrome (PCOS) according with the Rotterdam criteria. 3. Ovarian failure and subjects receiving donor oocytes/embryos 4. Anti-cardiolipid and/or lupus anti-coagulant abnormalities by history 5. Diabetes mellitus (Type I or Type II) 6. Untreated hypothyroidism 7. Hyperprolactinemia 8. Uncorrected uterine anomaly

Design outcomes

Primary

MeasureTime frameDescription
SIRT1 gene expression in the endometrium2-3 yearsEndometrial biopsy specimens will be stained for SIRT1 using immunostaining and Hscore assignment.

Secondary

MeasureTime frameDescription
BCL6 expression in the endometrium2-3 yearsEndometrial biopsy specimens will be stained for BCL6 using immunostaining and Hscore assignment.
Number of patients who have a positive pregnancy test (HCG level > 5) 9 days after embryo transfer2-3 yearspregnancy rate
Number of embryo transfers that lead to live births2-3 yearslive birth rate

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026